The study data shows that comprehensive management plays an important role in supporting good and quality survival for HAP patients. Treatment with drugs to reduce pressure in the pulmonary veins is the main drug that should be given to patients with HAP. Our research team, in collaboration with the Pulmonary Hypertension Working Group, the Central Board of the Indonesian Cardiovascular Specialist Doctors Association (PP PERKI), has succeeded in making a policy that HAP drugs, namely sildenafil, are registered with the JKN-BPJS, so that they can be widely administered to HAP patients (Lilyasari et al., 2019). The administration of sildenafil provides benefits to HAP patients by improving their quality of life (Hidayati et al., 2020).
After following the Collaborative and Multidisciplinary Approach Short Course, participants are expected to understand the basics and principles of pathophysiology, diagnosis, treatment, and prognosison current pulmonary hypertension and Formulate future challenges in the field of pulmonary hypertension, including the development of technological principles for research and application.
Registration : (closed)
